Akari Therapeutics (AKTX) Shareholder's Equity Growth (3y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.90% |
| Dec 31, 2025 | 151.02% |
| Jun 30, 2025 | 45.42% |
| Mar 31, 2025 | 16.00% |
| Dec 31, 2024 | 58.76% |
| Sep 30, 2024 | -37.31% |
| Jun 30, 2024 | -63.01% |
| Mar 31, 2024 | -42.65% |
| Sep 30, 2023 | -68.70% |
| Jun 30, 2023 | -22.43% |
| Mar 31, 2023 | 26.14% |
| Dec 31, 2022 | 517.73% |
| Jun 30, 2022 | 162.68% |
| Mar 31, 2022 | 42.23% |
| Dec 31, 2021 | 8.34% |
| Sep 30, 2021 | -55.50% |
| Jun 30, 2021 | -58.93% |
| Mar 31, 2021 | 177.42% |
| Sep 30, 2020 | -18.93% |
| Jun 30, 2020 | -36.12% |
| Mar 31, 2020 | -47.35% |
| Dec 31, 2019 | -93.94% |
| Sep 30, 2019 | -50.75% |
| Jun 30, 2019 | -77.55% |
| Mar 31, 2019 | -52.91% |
| Dec 31, 2018 | -55.24% |
| Sep 30, 2018 | 46.10% |
| Jun 30, 2018 | 186.69% |
| Mar 31, 2018 | -27.62% |
| Dec 31, 2017 | 115.45% |
| Jun 30, 2017 | 29.94% |
| Dec 31, 2016 | 339.87% |
| Dec 31, 2015 | 154.58% |
| Dec 31, 2014 | 42.52% |